Author Archive for: aattiya
About Amanda Attiya
Amanda Attiya is a research analyst with NASHP’s Emerging Policy Issues team. Prior to joining NASHP in June 2020, Amanda worked as an intern with the House Committee on Ways and Means, where she provided assistance to the Subcommittee on Health’s project on improving the quality of health services in rural and underserved regions. She also interned for US Sen. Tim Kaine (VA) and US Rep. Jeff Van Drew (NJ) where she conducted extensive legislative research. She now works on several NASHP projects addressing drug pricing, health system costs, and patient-centered outcomes research. Amanda graduated from George Mason University in 2020, where she was awarded a BS in public administration with a minor in health and social policy.
Entries by Amanda Attiya
Most state legislatures have adjourned after busy sessions focused on addressing the COVID-19 public health emergency. Nonetheless, lawmakers introduced over 200 bills to curb health system costs. Eighteen states and DC enacted 28 laws in 2021, with different strategies and frameworks to reign in rising healthcare costs in the United States.
Colorado, Louisiana, and Minnesota enacted laws this session enabling reverse auctions to procure a pharmacy benefit manager (PBM) for their state employee health plans (SEHPs). This approach to PBM procurement, first used by New Jersey, aims to achieve savings by encouraging PBMs to be more competitive on pricing in their bidding for contracts without reducing drug benefits for the state’s public employees. In the reverse auction procurement model, states design their own […]
Increased flexibility in the delivery and payment of telehealth across many coverage programs, but particularly in Medicaid and CHIP, throughout the COVID-19 pandemic has been a significant shift for some states. Many state officials are considering if and how to adapt rapidly implemented telehealth policies as the nation emerges from the public health emergency. Existing and emerging patient-centered research can help inform these important decisions.
The recent approval of the Alzheimer’s drug Aduhelm under the U.S. Food & Drug Administration’s (FDA) Accelerated Approval Program is controversial for a range of reasons, including its projected impact on state Medicaid budgets which will be required to cover the drug, priced at $56,000 a year, despite inconclusive evidence of its clinical effectiveness. While Aduhelm is the latest prescription drug to make headlines, state Medicaid programs have been seeking policy solutions to address high cost accelerated […]
Federal efforts to increase hospital price transparency are falling short as hospitals fail to fully comply with requirements. However, states with transparency laws that give them access to comprehensive hospital financial data are using the pricing information to more fully analyze hospitals’ fiscal health and inform states’ cost containment efforts.
The adoption and use of telehealth have exploded across states, spurred by the COVID-19 pandemic, the need for social distancing, and swift federal and state action to enable how telehealth is delivered and covered by insurers. These changes will have a lasting impact on how health care is delivered, affecting payers, medical providers, and patients […]
Amid intense scrutiny of 2020 Presidential election results, little attention has been paid to health-related state ballot initiatives. While COVID-19 limited citizens’ ability to collect signatures to get questions on the ballot, citizens and legislatures in nine states placed health care-related issues on their state ballots.
Low-income individuals and communities of color, already besieged by poor access to health care, limited insurance coverage, and other health inequities exposed by COVID-19, also suffer another health disparity – they are among the hardest hit by continually rising prescription drug prices. Since 2017, states across the nation have taken action to lower rising drug […]
In response to COVID-19, states have made swift and unprecedented changes to enable the use of telehealth to meet the public’s need to safely access care remotely. Now, policymakers face the challenge of analyzing whether to sustain these changes as they weigh cost, privacy, and security considerations and effectiveness of remote care delivery. As officials […]